Staph Intervention for Effective Local Defense

Description

Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The goal of this clinical trial is to evaluate a community-informed approach to reduce carriage of SA. Participants will be assigned to education and household supplies for prevention of SA with and without a biomedical intervention. Researchers will compare SA carriage in the two groups.

Conditions

Staphylococcus Aureus Infection

Talk to us

Study Overview

On this page

Study Details

Study overview

Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The goal of this clinical trial is to evaluate a community-informed approach to reduce carriage of SA. Participants will be assigned to education and household supplies for prevention of SA with and without a biomedical intervention. Researchers will compare SA carriage in the two groups.

SHIELD (Staph Intervention for Effective Local Defense): An Open-label Randomized Controlled Trial to Assess Efficacy of a Sustained Intervention (Topical Antibiotics and Skin Antisepsis) to Decrease Staphylococcus Aureus Carriage in Adults

Staph Intervention for Effective Local Defense

Condition
Staphylococcus Aureus Infection
Intervention / Treatment

-

Contacts and Locations

Whiteriver

Whiteriver Center for Indigenous Health, Whiteriver, Arizona, United States, 85941

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Native American adult living on or adjacent to the WMA Tribal lands
  • * 18 years of age and older
  • * Lab-confirmed SA carriage at time of enrollment
  • * Ability to provide written informed consent
  • * Ability to comply with follow-up activities
  • * Risk factor for SA-associated infection: Diagnosed with diabetes OR body mass index ≥30 OR documented SSTI or SA infection in the past 3 years
  • * Immediate family member of study staff
  • * Allergy to citrus or any ingredient in Nozin, Hibiclens, or mupirocin
  • * Without a permanent home (e.g., living in a group home, shelter, or is unhoused)
  • * Use of antibiotics within 30 days prior to the first study visit (time-limited)
  • * Current SA infection (time-limited)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins Bloomberg School of Public Health,

Laura Hammitt, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins Bloomberg School of Public Health

Study Record Dates

2026-01-01